Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Feb 4, 2022Enjaymo is the only approved treatment to decrease the need for red blood cell transfusion due to hemolysis, the destruction of red blood cells, in adults with cold agglutinin disease (CAD)
-
Feb 1, 2022Late-breaking pivotal data show significant disease improvements in eosinophilic esophagitis and also in chronic spontaneous urticaria
-
Jan 27, 2022- Company to Host Conference Call Tomorrow, January 28th at 8:00 AM ET -
-
Jan 20, 2022- PRV-3279 is Designed to Intercept B-Cell Mediated Autoimmune Diseases -
-
Jan 19, 2022Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting IL-4 and IL-13, central drivers of type 2 inflammation, to address itch and skin lesions
-
Dec 20, 2021